A retrospective study of statin use and its effectiveness in Taiwanese

Acta Cardiologica Sinica

Volumn 25, Issue 1, 2009, Pages 18-25

  Hsuan, Chin Feng ^a   Lee, Thung Lip ^a   Chang, Hsiu Ling ^a   Tseng, Wei Kung ^a,b   Wu, Chau Chung ^c,d  

^a E DA HOSPITAL   (Taiwan)

^b I SHOU UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Coronary heart disease; Lipid lowering; Statin

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ALLERGIC REACTION; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DRUG EFFICACY; DRUG USE; DYSLIPIDEMIA; FEMALE; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MEDICAL RECORD REVIEW; MYALGIA; PRACTICE GUIDELINE; PRESCRIPTION; RETROSPECTIVE STUDY; SIDE EFFECT; TAIWAN; TIME SERIES ANALYSIS;

EID: 66449083312     PISSN: 10116842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Verschuren WM, Jacobs DR, Bloemberg BP, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA 1995;274:131-136
2. Zhang X, Patel A, Horibe H, et al. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol 2003;32:563-572 (Pubitemid 37039010)
3. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density sub-fractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001;104:1108-1113 (Pubitemid 32830392)
4. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 2004;109(21Suppl 1):II27-33. (Pubitemid 38724153)
5. Torng PL, Su TC, Sung FC,et al. Effects of menopause on intraindividual changes in serum lipids, blood pressure, and body weight-the Chin-Shan Community Cardiovascular Cohort study. Atherosclerosis 2002;161:409-415 (Pubitemid 34219195)
6. Wang TD, Chen WJ, Chien KL, et al. Efficacy of cholesterol levels and ratios in predicting future coronary heart disease in a Chinese population. Am J Cardiol 2001;88:737-743
7. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-1307
8. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615-1622 (Pubitemid 28248586)
9. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389 (Pubitemid 24365311)
10. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-1009
11. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-1357
12. Xydakis AM, Jones PH. Use of statins for secondary prevention. Curr Treat Options Cardiovasc Med 2003;5:63-73.
13. Grundy SM. Primary prevention of coronary heart disease: role of cholesterol control in the United States. J Intern Med 1997;241:295-306. (Pubitemid 27223995)
14. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 ;360:7-22. (Pubitemid 34756487)
15. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-1158 (Pubitemid 36398384)
16. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504
17. LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-1435
18. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239 (Pubitemid 38924592)
19. Yin WH, Wang JJ, Jen HL, et al. Low use of statins in patients with acute myocardial infarction: a single center experience. Acta Cardiol Sin 2007;23:79-88. (Pubitemid 47235326)
20. Bureau of National Health websitehttp://www.bhp.doh.gov.tw/health91/ study-2.htm access date 2008.1.23
21. Van Ganse E, Laforest L, Alemao E, et al. Lipid-modifucation therapy and attainment in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin 2005;21:1389-1399 (Pubitemid 41368570)
22. Sloan KL, Sales AE, Willems JP, et al. Frequency of serum low-density lipoprotein cholesterol measurement and frequency of results < or = 100 mg/dl among patients who had coronary events (Northwest VA Network Study). Am J Cardiol 2001;88:1143-1146 (Pubitemid 33043847)
23. Banegas J, Vegazo O, Serrano P, et al. The gap between dyslipidemia control perceived by physicians and objective control patterns in Spain. Atherosclerosis 2006;188:420-424 (Pubitemid 44313923)